Cargando…
Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis
BACKGROUND: Helicobacter pylori (HP) has been considered to be one of the primary causes of gastric mucosa-associated lymphoid tissue (MALT) lymphoma since 1993. Low-grade gastric MALT lymphoma with HP is widely treated with HP eradication therapy, according to each specific clinical situation. Howe...
Autores principales: | Xie, Ya-Lin, He, Chun-Yan, Wei, Si-Qi, Guan, Wen-Ju, Jiang, Zheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289298/ https://www.ncbi.nlm.nih.gov/pubmed/32452892 http://dx.doi.org/10.1097/CM9.0000000000000813 |
Ejemplares similares
-
Role of non-Helicobacter pylori gastric Helicobacters in helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma
por: Lemos, Fabian Fellipe Bueno, et al.
Publicado: (2023) -
Helicobacter pylori recurrence after eradication in Latin America: Implications for gastric cancer prevention
por: Corral, Juan E, et al.
Publicado: (2017) -
Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis
por: Losurdo, Giuseppe, et al.
Publicado: (2018) -
Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
por: Gong, Eun Jeong, et al.
Publicado: (2016) -
Helicobacter pylori eradication: Exploring its impacts on the gastric mucosa
por: Weng, Chun-Yan, et al.
Publicado: (2021)